Tailong Pharmaceutical’s announcement on changes to the company’s “Drug Production License”
Securities code: 600222 Securities abbreviation: Tailong Pharmaceutical Announcement number: Lin 2026-002 Henan Tailong Pharmaceutical Co., Ltd.
Announcement on changes to the company's "Drug Production License"
The company's board of directors and all directors guarantee that the contents of this announcement do not contain any false records, misleading statements or major omissions, and assume legal responsibility for the authenticity, accuracy and completeness of its contents.
Henan Tailong Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") recently received the renewal of the "Drug Production License" from the Henan Provincial Food and Drug Administration. At the same time, it made changes to the production scope, production lines and entrustment status. The renewed "Drug Production License" is valid until December 31, 2030. The relevant information is now announced as follows:
1. Relevant circumstances of the renewed "Drug Production License"
Company name: Henan Tailong Pharmaceutical Co., Ltd.
License number: Yu 20150080
Unified social credit code: 91410000706786295N
Category code: AhztChDh
Residence (business place): No. 8 Jinsuo Road, Zhengzhou High-tech Industrial Development Zone Legal representative: Wang Rongtao
Person in charge of the company: Su Fengshan
Quality manager: Li Jianghua
Production person in charge: Zhang Lizhuang
Quality Authorizer: Li Jianghua
Valid until: December 31, 2030
Production address and production scope:
Securities code: 600222 Securities abbreviation: Tailong Pharmaceutical Announcement number: Lin 2026-002
No. 8 Jinsuo Road, Zhengzhou High-tech Industrial Development Zone: Mixtures (including oral liquids), lotions, syrups (including Chinese medicine pretreatment and extraction)
Zhulin Town, Gongyi City, Henan Province: APIs (including pre-processing and extraction of traditional Chinese medicine), tablets (including pre-processing and extraction of traditional Chinese medicine), hard capsules (including pre-processing and extraction of traditional Chinese medicine), skullcap extraction workshop, psychotropic drugs; granules (including pre-processing and extraction of traditional Chinese medicine) (limited to registration application use)
2. Changes to the copy of "Drug Production License"
The company's drug production license is re-issued: Production address 1: No. 8 Jinsuo Road, Zhengzhou High-tech Industrial Development Zone, production scope: mixtures (including oral liquids), lotions, syrups (including pre-processing and extraction of traditional Chinese medicine); production address 2: Zhulin Town, Gongyi City, Henan Province, production scope: API (Huperzine A) (including Chinese medicine pre-processing and extraction), tablets (including Chinese medicine pre-processing and extraction), hard capsules (including Chinese medicine pre-processing and extraction), skullcap extraction workshop, psychotropic drugs (estazolam tablets); granules (including Chinese medicine pre-processing and extraction) (limited to registration application use).
APIs (huperzine A) (including Chinese medicine pre-processing and extraction), hard capsules (including Chinese medicine pre-processing and extraction), psychotropic drugs (estazolam tablets), and granules (including Chinese medicine pre-processing and extraction) located in Zhulin Town, Gongyi City, Henan Province should apply for drug GMP compliance inspection before resuming production (marketing), and can be produced and marketed only after passing the test.
Production scope and production lines are reduced: mixtures and 9 APIs (sodium tanshinone IIA sulfonate, betastin besylate, adefovir dipivoxil, dronedarone hydrochloride, posaconazole, lubiprostone, rivaroxaban, febuxostat, and nebivolol hydrochloride) in Zhulin Town, Gongyi City, Henan Province. At the same time, the following reductions are made: the synthesis production line of raw materials.
Reduced scope of entrusted production: Accepted the entrustment of Henan Changshitang Pharmaceutical Co., Ltd., stock code: 600222, stock abbreviation: Tailong Pharmaceutical, announcement number: Lin 2026-002, berberine hydrochloride tablets (specification: 0.1g, national drug approval number H41023943) and metoclopramide tablets (specification: 5mg, national drug approval number) produced in Zhulin Town, Gongyi City, Henan Province H41020581), chlorzoxazone tablets (specification: 0.2g, national drug approval number H20063434).
3. Impact on the company and risk warning
The renewal of the "Drug Production License" is based on the expiration of the original license and the replacement of the original and duplicate "Drug Production License" is completed in accordance with the relevant provisions of the "Measures for the Supervision and Administration of Drug Production". Obtaining the new certificate ensures the company's normal production and operations. Changes in production scope, production lines and entrustment status will not have a significant impact on the company's existing production structure, and the company will continue to maintain stable production capacity. This renewal of the "Drug Production License" will not have a significant impact on the company's current performance.
Due to the industry characteristics of pharmaceutical products, the production and sales of pharmaceuticals may be affected by national policies, market environment changes and other factors, and there are uncertainties. Investors are advised to make prudent decisions and pay attention to preventing investment risks.
Announcement is hereby made.
Board of Directors of Henan Tailong Pharmaceutical Co., Ltd.
January 5, 2026